Innoviva, Inc.'s Form 4 filing
Entasis Therapeutics Holdings Inc. (ETTX) · filed Jul 13, 2022
- Accession no.
- 0001140361-22-025957
- Filed
- Jul 13, 2022, 9:27 PM ET
- Trade date
- Jul 8-11, 2022
- Filing delay
- 5 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $42.4M. It was filed 5 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Innoviva, Inc.CIK 0001080014 | 10% Owner |
| Innoviva Strategic Opportunities LLCCIK 0001842875 | Other: Former 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 8, 2022 | Common Stock | PPurchaseAcquired | +11,671,662 | $2.20 | +$25,677,656.4 | 21,671,662 | Indirect | |
| Jul 11, 2022 | Common Stock | PPurchaseAcquired | +7,598,814 | $2.20 | +$16,717,390.8 | 29,270,476 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.